2.94% -0.0499

Lexicon Pharmaceuticals Inc (LXRX)

Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten

Lexicon Pharmaceuticals Inc (LXRX)

Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten

HC Wainwright Reiterates “Buy” Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - Defense World

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Movies UK

BRIEF—Lexicon Pharmaceuticals resubmits sotagliflozin NDA | The Pharmaletter - The Pharma Letter

Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio

Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes - ForexTV.com

Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes - StockTitan

BRIEF—Lexicon Pharmaceuticals resubmits sotagliflozin NDA | The Pharmaletter - The Pharma Letter

Views of Wall Street's Leading Experts on Lexicon Pharmaceuticals Inc – Sete News - SETE News

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to Post Q2 2024 Earnings of ($0.18) Per Share, HC Wainwright ... - Defense World

How Much is Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) CEO Getting Paid? - Yahoo Movies Canada

Closing Figures: Lexicon Pharmaceuticals Inc (LXRX)'s Positive Finish at 1.75, Up 1.74 – DWinneX - The Dwinnex

Brokers Set Expectations for Lexicon Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:LXRX) - MarketBeat

Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association - ForexTV.com

Data From Lexicon's RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed ... - StockTitan

Data From Lexicon's RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed ... - StockTitan

Sanofi to pay Lexicon $260 million for terminated partnership - Yahoo Movies UK

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasted to Post FY2024 Earnings of ($0.65) Per Share - MarketBeat

LXRX’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle

Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal ... - StockTitan

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Expected to Earn FY2024 Earnings of ($0.65) Per Share - Defense World

Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal ... - StockTitan

Lexicon Pharmaceuticals Inc (LXRX) did well last session? – US Post News - US Post News

Lexicon Pharmaceuticals (NASDAQ:LXRX) Research Coverage Started at HC Wainwright - MarketBeat

HC Wainwright Initiates Coverage on Lexicon Pharmaceuticals (NASDAQ:LXRX) - Defense World

H.C. Wainwright starts Lexicon Pharmaceuticals stock at 'Buy', sees strong growth potential - Investing.com South Africa

H.C. Wainwright starts Lexicon Pharmaceuticals stock at 'Buy', sees strong growth potential By Investing.com - Investing.com

H.C. Wainwright starts Lexicon Pharmaceuticals stock at 'Buy', sees strong growth potential By Investing.com - Investing.com

How Much is Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) CEO Getting Paid? - Yahoo Movies Canada

Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association - ForexTV.com

Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored ... - StockTitan

Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored ... - StockTitan

Tango Therapeutics (TNGX) Moves 10.3% Higher: Will This Strength Last? - Yahoo Canada Finance

Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored ... - StockTitan

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Shares Bought by BVF Inc. IL - Defense World

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Shares Purchased by BVF Inc. IL - MarketBeat

Leerink Partners initates Lexicon Pharmaceuticals Inc (LXRX) stock to an Outperform – Knox Daily - Knox Daily

Financial Snapshot: Analyzing Lexicon Pharmaceuticals Inc (LXRX)'s Key Ratio Metrics – DWinneX - The Dwinnex

A better buy-in window may exist right now for Lexicon Pharmaceuticals Inc (LXRX) – Sete News - SETE News

LXRX’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle

Even after rising 8.0% this past week, Lexicon Pharmaceuticals (NASDAQ:LXRX) shareholders are still down 69% over the past five years - Simply Wall St

Are Lexicon Pharmaceuticals Inc'shares a good deal? – US Post News - US Post News

Do Institutions Own Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Shares? - Yahoo Canada Sports

Lexicon Pharmaceuticals (NASDAQ:LXRX) Upgraded by StockNews.com to "Sell" - MarketBeat

Lexicon Pharmaceuticals (NASDAQ:LXRX) Upgraded by StockNews.com to "Sell" - MarketBeat

Lexicon Pharmaceuticals (NASDAQ:LXRX) Upgraded to Sell by StockNews.com - Defense World

Get in on Lexicon Pharmaceuticals Inc's (LXRX) buy-in window today! – Sete News - SETE News

Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo New Zealand News

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Pass Above 200 Day Moving Average of $1.84 - MarketBeat

LXRX Shares Experience Surge in Value – Knox Daily - Knox Daily

Lexicon Pharmaceuticals (NASDAQ:LXRX) Upgraded by StockNews.com to "Sell" - MarketBeat

Ähnlich wie LXRX